Posted by Michael Wonder on 09 Aug 2025
Health Canada has authorised CSL's Andembry (garadacimab) as once monthly treatment for hereditary angioedema
8 August 2025 - CSL today announced that Health Canada has granted a marketing authorisation for Andembry (garadacimab) for routine prevention of attacks of hereditary angioedema in adult and paediatric patients aged 12 years and older.
The Health Canada authorisation is based on data from the pivotal placebo-controlled Phase 3 VANGUARD trial evaluating the efficacy and safety of Andembry.
